The importance of adjuvant formulation in the development of a tuberculosis vaccine

Journal of Immunology

Volumn 188, Issue 5, 2012, Pages 2189-2197

  Baldwin, Susan L ^a   Bertholet, Sylvie ^a,c   Reese, Valerie A ^a   Ching, Lance K ^a   Reed, Steven G ^a,b   Coler, Rhea N ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b Immune Design Corp   (United States)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; GAMMA INTERFERON; GLUCOPYRANOSYL LIPID ADJUVANT; ID93 PROTEIN; INTERLEUKIN 2; MYCOBACTERIUM VACCINE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG FORMULATION; EMULSION; FEMALE; GUINEA PIG; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; OIL IN WATER EMULSION; PRIORITY JOURNAL; SURVIVAL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; EMULSIONS; FEMALE; GUINEA PIGS; LIPID A; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; SURVIVAL ANALYSIS; TH1 CELLS; TH2 CELLS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, SUBUNIT;

EID: 84857482098     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102696     Document Type: Article

References (18)

1. World Health Organization. 2010. Global Tuberculosis Control 2010. WHO/ HTM/TB/2010.7. WHO, Geneva, Switzerland.
2. Vogel, F. R., C. Caillet, I. C. Kusters, and J. Haensler. 2009. Emulsion-based adjuvants for influenza vaccines. Expert Rev. Vaccines 8: 483-492.
3. Mbow, M. L., E. De Gregorio, N. M. Valiante, and R. Rappuoli. 2010. New adjuvants for human vaccines. Curr. Opin. Immunol. 22: 411-416.
4. Rowland, R., and H. McShane. 2011. Tuberculosis vaccines in clinical trials. Expert Rev. Vaccines 10: 645-658.
5. Coler, R. N., S. Bertholet, M. Moutaftsi, J. A. Guderian, H. P. Windish, S. L. Baldwin, E. M. Laughlin, M. S. Duthie, C. B. Fox, D. Carter, et al. 2011. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6: e16333.
6. Pantel, A., C. Cheong, D. Dandamudi, E. Shrestha, S. Mehandru, L. Brane, D. Ruane, A. Teixeira, L. Bozzacco, R. M. Steinman, and P. M. Longhi. 2011. A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. Eur. J. Immunol. In press.
7. Bertholet, S., G. C. Ireton, D. J. Ordway, H. P. Windish, S. O. Pine, M. Kahn, T. Phan, I. M. Orme, T. S. Vedvick, S. L. Baldwin, et al. 2010. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrugresistant Mycobacterium tuberculosis. Sci. Transl. Med. 2: 53ra74.
8. Bertholet, S., G. C. Ireton, M. Kahn, J. Guderian, R. Mohamath, N. Stride, E. M. Laughlin, S. L. Baldwin, T. S. Vedvick, R. N. Coler, and S. G. Reed. 2008. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J. Immunol. 181: 7948-7957.
9. Williams, A., Y. Hall, and I. M. Orme. 2009. Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb.) 89: 389-397.
10. Baldwin, S. L., S. Bertholet, M. Kahn, I. Zharkikh, G. C. Ireton, T. S. Vedvick, S. G. Reed, and R. N. Coler. 2009. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 27: 3063-3071.
11. Shackelford, C., G. Long, J. Wolf, C. Okerberg, and R. Herbert. 2002. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol. Pathol. 30: 93-96. (Pubitemid 34194564)
12. Ching, L. K., F. Mompoint, J. A. Guderian, A. Picone, I. M. Orme, R. N. Coler, S. G. Reed, and S. L. Baldwin. 2011. Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay. J. Immunol. Methods 373: 54-62.
13. Parida, S. K., and S. H. Kaufmann. 2010. Novel tuberculosis vaccines on the horizon. Curr. Opin. Immunol. 22: 374-384.
14. Coler, R. N., S. L. Baldwin, N. Shaverdian, S. Bertholet, S. J. Reed, V. S. Raman, X. Lu, J. DeVos, K. Hancock, J. M. Katz, et al. 2010. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5: e13677.
15. Wiley, S. R., V. S. Raman, A. Desbien, H. R. Bailor, R. Bhardwaj, A. R. Shakri, S. G. Reed, C. E. Chitnis, and D. Carter. 2011. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3: 93ra69.
16. Bertholet, S., Y. Goto, L. Carter, A. Bhatia, R. F. Howard, D. Carter, R. N. Coler, T. S. Vedvick, and S. G. Reed. 2009. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27: 7036-7045.
17. Agger, E. M., J. P. Cassidy, J. Brady, K. S. Korsholm, C. Vingsbo-Lundberg, and P. Andersen. 2008. Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. Immunology 124: 175-185. (Pubitemid 351692898)
18. Rook, G. A., K. Dheda, and A. Zumla. 2005. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat. Rev. Immunol. 5: 661-667. (Pubitemid 41113197)